MetLife Investment Management’s Atea Pharmaceuticals AVIR Stock Holding History

MetLife Investment Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$214K	Buy	39,778 +10,060	+34%	+$46.2K	﹤0.01%	2188
2025 Q4	$106K	Sell	29,718 -16,227	-35%	-$51.6K	﹤0.01%	2576
2025 Q3	$133K	Buy	45,945 +420	+0.9%	+$1.43K	﹤0.01%	2522
2025 Q2	$164K	Buy	45,525 +69	+0.2%	+$206	﹤0.01%	2287
2025 Q1	$136K	Buy	45,456 +8,365	+23%	+$26.1K	﹤0.01%	2385
2024 Q4	$124K	Sell	37,091 -8,109	-18%	-$26.9K	﹤0.01%	2524
2024 Q3	$151K	Hold	45,200	–	–	﹤0.01%	2433
2024 Q2	$150K	Buy	45,200 +7,475	+20%	+$27.9K	﹤0.01%	2413
2024 Q1	$152K	Sell	37,725 -9,509	-20%	-$37.2K	﹤0.01%	2336
2023 Q4	$144K	Hold	47,234	–	–	﹤0.01%	2415
2023 Q3	$142K	Hold	47,234	–	–	﹤0.01%	2398
2023 Q2	$177K	Hold	47,234	–	–	﹤0.01%	2354
2023 Q1	$158K	Hold	47,234	–	–	﹤0.01%	2357
2022 Q4	$227K	Hold	47,234	–	–	﹤0.01%	2172
2022 Q3	$269K	Buy	47,234 +8,168	+21%	+$62.5K	﹤0.01%	2099
2022 Q2	$277K	Hold	39,066	–	–	﹤0.01%	2074
2022 Q1	$282K	Buy	39,066 +14,418	+58%	+$97.9K	﹤0.01%	2128
2021 Q4	$220K	Hold	24,648	–	–	﹤0.01%	1992
2021 Q3	$864K	Hold	24,648	–	–	0.01%	1196
2021 Q2	$529K	Buy	24,648 +19,099	+344%	+$574K	﹤0.01%	1537
2021 Q1	$343K	Sell	5,549 -1,387	-20%	-$93.7K	﹤0.01%	1740
2020 Q4	$290K	Buy	+6,936	New	+$224K	﹤0.01%	1785

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MetLife Investment Management's AVIR Position: Q1 2026 in Review

MetLife Investment Management increased its Atea Pharmaceuticals (AVIR) stake by 34% in Q1 2026, buying an estimated $46.2K and bringing the position to 39,778 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #2188.

MetLife Investment Management first reported a position in AVIR in Q4 2020 and has held it in 22 quarters since. The position peaked at $864K in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

MetLife Investment Management held 39,778 shares of Atea Pharmaceuticals worth $214K as of Q1 2026.
MetLife Investment Management bought 10,060 Atea Pharmaceuticals shares in Q1 2026, an estimated $46.2K.
Atea Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2188 holding.
MetLife Investment Management first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
MetLife Investment Management's Atea Pharmaceuticals position peaked at $864K in Q3 2021.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.